Northwell Health will host its eighth annual Constellation Forum in New York City on October 22 and 23, focusing on the emerging field of bioelectronic medicine. The event is set to bring together scientists, innovators, investors, government officials, and industry leaders to discuss advancements in using medical devices rather than pharmaceuticals to treat diseases.
The forum will be led by John D’Angelo, MD, Northwell’s president and CEO. Speakers from organizations such as the Food and Drug Administration (FDA), Medtronic, Cleveland Clinic, Centers for Medicare & Medicaid Services (CMS), SetPoint Medical, and Karolinska Institutet are scheduled to share their perspectives. The sessions will address scientific breakthroughs, commercialization strategies, investment opportunities, and challenges involved in expanding bioelectronic medicine into routine care.
“Innovation, the kind that transforms health care, flourishes when we bring different perspectives together. At Northwell’s Constellation Forums, we’ve seen how converging clinical and scientific expertise with creative thinking leads to breakthroughs,” said Dr. D’Angelo. “I know this year’s Forum will generate new solutions and drive life-changing treatment options that were once unimaginable and will benefit our communities for years to come.”
This year’s forum follows the FDA’s recent approval of a vagus nerve stimulation device designed for rheumatoid arthritis patients. The technology was developed by SetPoint Medical based on over thirty years of research led by Kevin J. Tracey, MD—president and CEO of Northwell’s Feinstein Institutes for Medical Research—as well as other researchers globally. Dr. Tracey is expected to speak about translating scientific discoveries into practical therapies and discuss the significance of FDA approval for SetPoint Medical’s device within the broader context of bioelectronic medicine.
Additional speakers at the forum include Ami Bhatt (American College of Cardiology), Leonard Calabrese (Cleveland Clinic), Jeff Dunkel (Optain Health), Bunny Ellerin (Digital Health NY), Kristoffer Famm (Galvani Bioelectronics), Scott Gottlieb (former FDA commissioner), Hubert Lim (University of Minnesota), Geoffrey Ling (Ling and Associates), Josh Makower (Stanford Biodesign), Juan-Pablo Mas (Action Potential Venture Capital), John M. O’Brien (National Pharmaceutical Council), Peder Olofsson (Karolinska Institutet), Kelly Owens (clinical trial participant), Scott Rechler (RXR), Amaza Reitmeier (Medtronic), Amy Rochlin (Complex Disorders Alliance), Zack Scott (Norwest), Murthy Simhambhatla (SetPoint Medical) and Amy Turner (CMS Innovation Center). Lt. Col. Adam Willis from DARPA Biological Technologies Office is also among those scheduled to present.
